ABUS vs KMI · P/E 5.4, rev $6.2M vs P/E 24, $62.53B cap
Arbutus Biopharma Corp (ABUS) versus Kinder Morgan Inc (KMI) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Kinder Morgan Inc (KMI) is a oil & gas midstream company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
KMI does not have a complete income-statement cache yet.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. KMI currently screens at market cap $62.53B and trailing P/E 24.2.
Not investment advice. Open the ABUS and KMI stock pages for the full models.
Not investment advice.